Trials / No Longer Available
No Longer AvailableNCT02712567
SARC021C: A Continuation Study of TH-CR-406/SARC021
A Continuation Study of TH-CR-406/SARC021 for the Remaining Subjects Enrolled in TH-CR-406/SARC021 in the US
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Sarcoma Alliance for Research through Collaboration · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- —
Summary
SARC021C is a nonrandomized, open-label, multicenter, continuation study designed to provide access to TH-302 for patients currently receiving and benefiting from single agent TH-302 therapy as part of the Phase III TH-CR-406/SARC021 study.
Detailed description
The goal of this study is to provide continuation therapy with TH-302 to patients with soft tissue sarcomas who obtained response or stabilization of disease with prior treatment on TH-CR-406/SARC021 protocol. After written informed consent has been obtained and eligibility has been established, patients will receive the study drug as part of the continuation study. Patients will receive treatment on study as long as they have clinical benefit and do not experience unacceptable toxicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Th-302 | 300 mg/m2 IV on Days 1 and 8 of a 21-day cycle. |
Timeline
- First posted
- 2016-03-18
- Last updated
- 2016-10-13
Source: ClinicalTrials.gov record NCT02712567. Inclusion in this directory is not an endorsement.